Allosteric Bioscience is a biopharmaceutical company focused on using the Quantum Computer and advanced Artificial Intelligence integrated with biomedical sciences such as genetics, genomics, cell biology and others, for improving and optimizing the aging and longevity process.

“Allosteric Bioscience is very pleased to be working with PolarisQB on quantum computing and advanced AI for its primary program of Optimizing the Aging and Longevity Molecular Process.

Using quantum computing and advanced AI technology with PolarisQB, we explored a chemical space that was previously undefined, leading to the discovery of novel molecules much faster than expected.”

Dr. Arthur Bollon, President and Co-Founder

Auransa is a clinical stage, AI-native biopharma that mines massive data to advance novel therapies that raise the standard of cancer care and build drug discovery programs that meet the needs of all cancer patients.

“We are excited about collaborating with PolarisQB to undertake a neglected area in the pharmaceutical industry. As women CEOs, we’ve joined forces to tackle female diseases like endometriosis, polycystic ovary syndrome, triple negative breast cancer or ovarian cancer.

The ability to explore a chemical space of 10³⁰ with PolarisQB’s quantum computing technology led to rapid identification of viable drug candidates, significantly accelerating our research timeline.

Together, I believe that we will be able to combine our expertise in biology and chemistry to generate quality solutions for hard to tackle or neglected diseases affecting women’s health.”

Pek Lum, Ph.D., CEO

PhoreMost has developed a next-generation phenotypic screening platform which can discern the best new targets for future therapies and, crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancers and other diseases of unmet need.

“This partnership represents the ultimate ambition for any collaboration between biology and technology, where the full diversity of newly identified druggable disease targets generated by biological PROTEINi shape-libraries can now be married to the most logical and rapid method of finding small-molecule drugs to them.

This best-in-class intersection of biotech and AI is going to be an exciting and transformative milestone for the entire pharmaceutical industry.”

Chris Torrance, CEO, Phoremost